CIAM
TBPH

Caitong International Asset Management’s Theravance Biopharma TBPH Stock Holding History

Caitong International Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
1,032
+928
+892% +$15.4K ﹤0.01% 1019
2026
Q1 		$1.69K Sell
104
-4,029
-97% -$71.3K ﹤0.01% 1276
2025
Q4 		$77.3K Buy
4,133
+1,408
+52% +$23.4K 0.02% 542
2025
Q3 		$39.8K Buy
2,725
+1,411
+107% +$17.8K 0.03% 399
2025
Q2 		$14.5K Buy
1,314
+1,056
+409% +$10.3K 0.01% 596
2025
Q1 		$2.3K Buy
+258
New +$2.4K ﹤0.01% 1283

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caitong International Asset Management's TBPH Position: Q2 2026 in Review

Caitong International Asset Management increased its Theravance Biopharma (TBPH) stake by 892% in Q2 2026, buying an estimated $15.4K and bringing the position to 1,032 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

Caitong International Asset Management first reported a position in TBPH in Q1 2025 and has held it in 6 quarters since. The position peaked at $77.3K in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Caitong International Asset Management held 1,032 shares of Theravance Biopharma worth $17.5K as of Q2 2026.
  • Caitong International Asset Management bought 928 Theravance Biopharma shares in Q2 2026, an estimated $15.4K.
  • Theravance Biopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1019 holding.
  • Caitong International Asset Management first reported a position in Theravance Biopharma in Q1 2025 and has held it in 6 quarters since.
  • Caitong International Asset Management's Theravance Biopharma position peaked at $77.3K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.